Preclinical CRO Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Preclinical CRO Market is Segmented by Service (Toxicology Testing, Bioanalysis and Drug Metabolism and Pharmacokinetics Studies, Safety Pharmacology, and Other Services), Mode Type (Patient-Derived Organoid (PDO) Models and Patient-Derived Xenograft (PDX) Models), End Users (Biopharmaceutical Companies, Research Institutes and Universities, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Industry Report Provides the Value (in USD Billion) for the Above Segments.

Preclinical CRO Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Preclinical CRO Market Size

Preclinical CRO Market Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 7.63 Billion
Market Size (2030) USD 10.92 Billion
CAGR (2025 - 2030) 7.44 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Low

Major Players

Preclinical CRO Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Preclinical CRO Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Preclinical CRO Market Analysis

The Preclinical CRO Market size is estimated at USD 7.63 billion in 2025, and is expected to reach USD 10.92 billion by 2030, at a CAGR of 7.44% during the forecast period (2025-2030). This growth is primarily driven by increasing research and development (R&D) expenditure worldwide, increasing the number of drugs in preclinical trials, and high demand for medicines uptake by chronically ill patients between 2025 and 2030.

Pharmaceutical companies are ramping up their research and development (R&D) spending to pioneer advanced treatments for various chronic diseases. This surge in R&D investment is driven by comprehensive drug discovery initiatives. These initiatives encompass not only the identification and development of potential chronic disease treatments but also the execution of preclinical studies, the design of clinical trials, and the navigation of regulatory approvals. For instance, in the Union Budget for 2023-2024, the Indian Ministry of Science and Technology earmarked INR 40 billion (USD 427.20 million) for the Department of Biotechnology (DBT). Out of this, an allocation of INR 11 billion (USD 130.48 million) was directed mainly towards biotechnology research and development, as well as fostering industrial and entrepreneurial growth in the nation.


This notable surge in funding is largely attributed to the escalating R&D expenditures across the country. Consequently, as R&D spending rises, there's an anticipated uptick in the adoption of preclinical CRO services, aimed at curtailing the overall costs associated with drug development.


As the number of drugs in preclinical stages rises, there's a growing trend to outsource preclinical services. This strategy aims to cut development costs and boost the likelihood of drug approval for subsequent clinical trials. For instance, data updated in January 2024 from ClinicalTrials.gov reveals that nearly 479,000 clinical studies were registered worldwide. This surge in clinical trials underscores the volume of therapeutics and medical devices that have successfully navigated preclinical trials and secured New Drug Application (NDA) approvals. Thus, with the uptick in drugs entering preclinical trials, the preclinical CRO industry is poised for growth in the coming years.


As the number of drugs in preclinical trials for diseases like cardiovascular issues and overactive bladder rises, the demand for preclinical CRO services is set to surge. This uptick aims to expedite the drug development process, thereby propelling the preclinical CRO market growth during 2024 to 2029. However, a lack of standardization and monitoring issues coupled with stringent regulatory policies are expected to hinder the market growth over the forecast period.

Preclinical CRO Industry Overview

The global market is very competitive, with most market leaders and players competing to maximize their market shares. Key players in the preclinical CRO market research are Charles River Laboratories, Labcorp Drug Development, Thermo Fisher Scientific Inc. (Pharmaceutical Product Development (PPD)), NorthEast BioAnalytical Laboratories LLC, Parexel International Corporation, Medpace, Eurofins Scientific, WuXi App Tec, ICON PLC, SGS SA, PharmaLegacy Laboratories, and Altasciences Company Inc., among others.


Currently, several major players offer significant research services and expand their clinical research support to the CRO industry, which is beneficial in various preclinical studies. With the emergence of advanced services, the market value of these key players increases, ultimately accentuating the competition.


For instance, in October 2023, Altasciences completed its laboratory facilities in Columbia, Missouri. This will supplement the service offering already available at Altasciences’ site in Seattle, Washington, to support preclinical and clinical studies conducted in the United States.


Consequently, strategic expansions by key companies are set to drive market growth and influence market trends during the forecast period.

Preclinical CRO Market Leaders

  1. Labcorp Drug Development

  2. Eurofins Scientific

  3. WuXi App Tec

  4. SGS SA

  5. Charles River Laboratories

  6. *Disclaimer: Major Players sorted in no particular order
Preclinical CRO Market Competitive Landscape
Need More Details on Market Players and Competiters?
Download PDF

Preclinical CRO Market News

  • August 2024: Silo Pharma, Inc., a biopharmaceutical company collaborated with WuXi AppTec (Hong Kong) Limited, a prominent global contract research organization (CRO). This partnership centers on a preclinical small animal study for SPU-16, a peptide designed to target the central nervous system (CNS) and aimed at addressing multiple sclerosis (MS). Furthermore, Silo Pharma is propelling the SPU-16 liposomal homing peptide's development, backed by a commercial evaluation license and option agreement with the University of Maryland, Baltimore (UMB).
  • March 2024: PsychoGenics Inc., a contract research organization (CRO) specializing in the central nervous system (CNS) focused preclinical and translational drug discovery services, is pleased to introduce its updated corporate identity and brand. This rebranding highlights the company's extensive knowledge and tailored solutions aimed at uncovering innovative CNS treatments for biopharmaceutical firms, government entities, and disease research organizations.
  • January 2024: Frontage Laboratories acquired Accelera S.r.l.’s Bioanalytical and DMPK businesses. Through this acquisition, Frontage Laboratories leverages preclinical studies services and clinical bioanalysis services offered by Accelera to increase its customers in Europe.
  • November 2023: Ichor Life Sciences, a comprehensive contract research organization (CRO) and a pioneer in longevity biotechnology, unveiled its new venture: Ichor Clinical Trial Services. With the establishment of Ichor Clinical, the company extends its expertise, catering to biotechnology and pharmaceutical clients and guiding them from initial preclinical studies to advanced clinical trials and FDA approvals.

Preclinical CRO Market Report - Table of Contents

1. Study Assumptions and Market Definition

  • 1.1 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Research and Development (R&D) Expenditure Worldwide
    • 4.2.2 Increase in Number of Drugs in Preclinical Trials
    • 4.2.3 High Demand for Medicines Uptake by Chronically Ill Patients
  • 4.3 Market Drivers
    • 4.3.1 Lack of Standardization and Monitoring Issue
    • 4.3.2 Stringent Regulatory Policies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value in USD Billion)

  • 5.1 By Service
    • 5.1.1 Toxicology Testing
    • 5.1.2 Bioanalysis and Drug Metabolism and Pharmacokinetics Studies
    • 5.1.3 Safety Pharmacology
    • 5.1.4 Other Services
  • 5.2 By Mode Type
    • 5.2.1 Patient Derived Organoid (PDOs) Models
    • 5.2.2 Patient-derived Xenograft (PDX) Models
  • 5.3 By End Users
    • 5.3.1 Biopharmaceutical Companies
    • 5.3.2 Research Institutes and Universities
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Charles River Laboratories
    • 6.1.2 Labcorp Drug Development
    • 6.1.3 Thermo Fisher Scientific Inc. (Pharmaceutical Product Development (PPD))
    • 6.1.4 NorthEast BioAnalytical Laboratories LLC
    • 6.1.5 Parexel International Corporation
    • 6.1.6 Medpace
    • 6.1.7 Eurofins Scientific
    • 6.1.8 WuXi App Tec
    • 6.1.9 ICON PLC
    • 6.1.10 SGS SA
    • 6.1.11 PharmaLegacy Laboratories
    • 6.1.12 Altasciences Company Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Preclinical CRO Industry Segmentation

As per the scope of this report, preclinical contract research organizations (CROs) specialize in ensuring a seamless procedure with reliable results for each test. Prior to entering clinical trials (or receiving other approvals like 510Ks) or being used for human care, preclinical CROs assist new medical product developers in demonstrating their products' safety and efficacy in live models that the FDA considers approximate as closely as possible the human anatomy.


The preclinical CRO market is segmented by service, mode type, end users, and geography. By service, the market is segmented into toxicology testing, bioanalysis and drug metabolism and pharmacokinetics studies, safety pharmacology, and other services. By mode type, the market is segmented into patient-derived organoid (PDO) models and patient-derived xenograft (PDX) models. By end user, the market is segmented into biopharmaceutical companies, research institutes and universities, and other end users. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value in USD for the above segments. The report offers the value (in USD Billion) for the above segments. By Service Bioanalysis and Drug Metabolism and Pharmacokinetics Studies Safety Pharmacology Other Services By Mode Type Bioanalysis and Drug Metabolism and Pharmacokinetics Studies Safety Pharmacology By End Users Biopharmaceutical Companies Research Institutes and Universities Other End Users By Geography North America United States Canada Mexico Europe Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific China Japan India Australia South Korea Rest of Asia Pacific Middle East & Africa GCC South Africa Rest of Middle East & Africa South America Brazil Argentina Rest of South America

By Service Toxicology Testing
Bioanalysis and Drug Metabolism and Pharmacokinetics Studies
Safety Pharmacology
Other Services
By Mode Type Patient Derived Organoid (PDOs) Models
Patient-derived Xenograft (PDX) Models
By End Users Biopharmaceutical Companies
Research Institutes and Universities
Other End Users
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Preclinical CRO Market Research Faqs

How big is the preclinical CRO market?

The preclinical CRO market size is estimated at USD 7.63 billion in 2025, and is expected to reach USD 10.92 billion by 2030, growing at a CAGR of 7.44% during the forecast period (2025-2030).

What is preclinical CRO?

Preclinical Contract Research Organizations (CROs) play a pivotal role in the early stages of drug development, conducting evaluations and tests prior to clinical trials. Catering to pharmaceutical and biotech firms, these CROs offer vital services, including project management, toxicology studies, safety assessments, and ensuring regulatory compliance.

Who are the leading players in the preclinical CRO market?

Key players include Eurofins Scientific, Charles River Laboratories, WuXi Apptec, Labcorp Drug Development, and SGS SA among others.

What challenges does the preclinical CRO market face? 

The challenges faced by the preclinical CRO market are a lack of standardization and monitoring issues coupled with stringent regulatory policies.

What innovations are emerging in the preclinical CRO space?

The emergence of artificial intelligence, automation, and advanced bioanalytical techniques are a few of the advanced innovations in the preclinical CRO space.

Preclinical CRO Market Report Snapshots